VSTM - Verastem, Inc.
| Previous Close | 3.3800 |
| Open | 3.3900 |
| Bid | 3.45 x 4000 |
| Ask | 3.46 x 900 |
| Day's Range | 3.2600 - 3.4800 |
| 52 Week Range | 2.7700 - 10.3500 |
| Volume | 2,036,947 |
| Avg. Volume | 2,309,327 |
| Market Cap | 255.318M |
| Beta (3Y Monthly) | 3.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.39 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.75 |
- Motley Fool•10 days ago
Here's Why Verastem Tumbled 34.1% in December
Investors have been worried about a difficult new drug launch.
- ACCESSWIRE•12 days ago
4 Healthcare Stocks Looking To Set January Highs
CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare is something crucial to the health and wellness of every living person, presenting a dire need for companies on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.
- Business Wire•14 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 19,467 shares of its common stock to three new employees and 22,200 restricted stock units (RSUs) to one new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $3.61 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on January 2, 2019 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- Benzinga•18 days ago
The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...
- GlobeNewswire•18 days ago
New Research: Key Drivers of Growth for The Blackstone Group, Barnes & Noble, Verastem, Littelfuse, Essendant, and Anworth Mortgage Asset — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•18 days ago
Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today highlighted the company’s recent progress and outlined strategic priorities for 2019. “We are pleased with the strong vote of confidence we have received in duvelisib, including validating licensing agreements in key Asian markets, recognition of our pivotal Phase 3 data in the medical journal Blood, and more.
- Business Wire•19 days ago
Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:00 a.m. PST in San Francisco, CA. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. Verastem Oncology (VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.
- Insider Monkey•last month
Hedge Funds Are Crazy About Verastem Inc (VSTM)
A market correction in the fourth quarter, spurred by a number of global macroeconomic concerns and rising interest rates ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller companies were especially hard hit during this time as investors fled to investments seen as being […]
- Simply Wall St.•last month
Have Insiders Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
- Business Wire•last month
Verastem Oncology Added to the NASDAQ Biotechnology Index®
Verastem, Inc. , a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® .
- Business Wire•last month
Verastem Oncology Announces First Recipient of the Care Differently Award for Excellence in Patient Support and Education
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, awarded the first annual Care Differently Award to Brian Koffman, M.D., a retired physician and clinical professor, who is a well-known educator in the chronic lymphocytic leukemia (CLL) community. Dr. Koffman is also the founder and volunteer Medical Director of the nonprofit CLL Society (CLLS). “We are pleased to announce Dr. Koffman as the inaugural recipient of the Care Differently Award, which recognizes individuals who go the extra mile to positively impact the lives of people living with cancer,” said Robert Forrester, President and Chief Executive Officer of Verastem Oncology.
- Business Wire•2 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its common stock to four employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.21 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on December 3, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- Business Wire•2 months ago
Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting
Multiple Clinical Data Presentations Highlighting Updated Long-Term Follow-Up from the Phase 3 DUO and the DUO Crossover Extension Studies
- Business Wire•2 months ago
Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from an investigator sponsored trial, led by Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center (MSK), evaluating duvelisib in combination with romidepsin in patients with relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) at the American Society of Hematology (ASH) 2018 Annual Meeting, taking place December 1-4, 2018, in San Diego. Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.
- Zacks•2 months ago
Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
Is (VSTM) Outperforming Other Medical Stocks This Year?
- Business Wire•2 months ago
Verastem Oncology Reports Third Quarter 2018 Financial Results
Quarter Highlighted by FDA Approval of COPIKTRA™ Capsules
- Business Wire•2 months ago
Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma (PTCL), an aggressive type of non-Hodgkin lymphoma (NHL). Verastem Oncology’s duvelisib was selected for the LLS’s Therapy Acceleration Program® (TAP) which provides additional resources to support the development of therapies for patients with blood cancers.
- Business Wire•3 months ago
Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a poster presentation of preclinical data by Jonathan Pachter, Ph.D., the Company’s Chief Scientific Officer, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C. “We have assessed the activity of duvelisib, our orally-administered dual inhibitor of PI3K-delta and PI3K-gamma, in combination with either immune checkpoint or co-stimulatory antibodies in syngeneic antitumor models,” said Dr. Pachter. “Results to be presented at SITC’s 33rd Annual Meeting demonstrated that duvelisib shows strong anti-tumor synergy with PD-1 or OX40 antibodies.
- Business Wire•3 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 6,153 shares of its common stock to one new employee and 40,000 restricted stock units (RSUs) to another new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.18 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on November 1, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- ACCESSWIRE•3 months ago
Cannabis and Biotech Firms Making Investors Boatloads
HENDERSON, NV / ACCESSWIRE / November 1, 2018 / With so many opportunities at excellent entry points we decided highlighting one of the more interesting companies on the market, Endonovo Therapeutics, Inc. (ENDV). There are several other diseases the Sofpulse might help with including counteracting the effects of nonalcoholic steatohepatitis (NASH). In a pre-clinical study, one to 2 weeks of treatment with Sofpulse®, the non-invasive proprietary device of Endonovo Therapeutics, appeared to counteract several of the disease signs associated with NASH-associated liver damage.
- Business Wire•3 months ago
Verastem Oncology Announces Data Presentations at the American Society of Hematology 2018 Annual Meeting
− Clinical Study Evaluating the Use of Duvelisib in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma to be Highlighted in an Oral Presentation −
- Zacks•3 months ago
What's in Store for Verastem (VSTM) This Earnings Season?
On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.
- GlobeNewswire•3 months ago
New Research Coverage Highlights Zoetis, TripAdvisor, The Gap, Unit, WestRock, and Verastem — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•3 months ago
Verastem Oncology Announces Executive Leadership Appointments and Changes
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Ironwood Pharmaceuticals, Inc.’s Chief Financial Officer Gina Consylman to its Board of Directors. Ms. Consylman, who will also serve as the Chair of the Board’s Audit Committee, replaces Louise Phanstiel who is leaving the Board to pursue other professional opportunities.
